To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
33 Current news of Pfizerrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
New programme aims to help companies increase productivity with technology solutions for pharmaceutical and chemical sectors
Pfizer Asia Pacific Pte. Ltd, Glaxo Wellcome Manufacturing Pte. Ltd. and Siemens Pte. Ltd, have signed on as founding members of a new A*STAR R&D Consortium Programme - Innovative Processing of Specialties and Pharmaceuticals (iPSP). Launched by A*STAR’s Institute of Chemical and Engineering ...
The club moss Lycopodium serratum is a creeping, flowerless plant used in homeopathic medicine to treat a wide variety of ailments. It contains a potent brew of alkaloids that have attracted considerable scientific and medical interest. However, the plant makes many of these compounds in ...
Company Exceeds Initial Goal - Pledges 20 Percent Reduction Between Now and 2012
The U.S. Environmental Protection Agency (EPA) honored Pfizer Inc in recognition of the company’s award-winning Energy and Climate Change Program, which reduced total greenhouse gas emissions by 43 percent per million dollars of revenue from 2000 to 2007. These reductions, which exceeded ...
Hikal Ltd. announced that it has completed a contract manufacturing agreement for supply of active pharmaceutical ingredients (API's) with Pfizer Inc. "We are extremely pleased to be selected as a long term contract manufacturer by Pfizer", said Jai Hiremath, Vice Chairman & Managing Director of ...
Pfizer Inc and Taisho Pharmaceutical Co., Ltd. have signed a definitive agreement, which replaces the letter of intent previously signed between the companies, for worldwide (excluding Japan) collaboration to research, develop and commercialize TS-032, a new schizophrenia drug candidate ...
Acquisition Will Expand Pfizer's Investment in Vaccines
Pfizer Inc announced it has entered into an agreement to acquire Coley Pharmaceutical Group, Inc., a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and ...
Companies Will Jointly Conduct Phase III Development and Commercialization of DGAT-1 Inhibitor Compounds
Pfizer Inc and Bristol-Myers Squibb Company announced that they have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors. Pfizer's DGAT-1 discovery program includes advanced pre-clinical compounds with potential applications ...
Pfizer Inc said that the High Court in Dublin, Ireland has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision, which is subject to a possible appeal, prevents Ranbaxy ...
Company to Focus on Accelerating Development and Commercialization of Strong Early- and Mid-Stage Pipeline
Pfizer said that the President of Pfizer Global Research and Development, Dr. John LaMattina, who made many important contributions to the Company's research division throughout his 30-year career, will retire from Pfizer by the end of this year. The company will begin a search both inside and ...
Pfizer said that Constance J. Horner, a member of the company's Board of Directors since 1993, has been elected lead director effective February 23. She succeeds Dr. Stanley O. Ikenberry, who has announced plans to retire from the board effective March 22, 2007 in accordance with Pfizer's ...